YIDU TECH (02158) Wins Phase III Clinical Research Project for Recombinant Human Nerve Growth Factor (SMR001) Eye Drops

Stock News
09/23

YIDU TECH (02158) announced that its affiliated company, Tianjin Happy Life Technology Co., Ltd., has successfully secured the Phase III clinical research project for recombinant human nerve growth factor (SMR001) eye drops from Shandong Yandu Biotechnology Co., Ltd. The total project value amounts to approximately RMB 55.8176 million.

As a leading driver of AI medical transformation in China, YIDU TECH upholds the mission of "making precision medicine accessible to everyone" and develops professional, efficient, precise, and inclusive medical artificial intelligence products and solutions. Based on the company's proprietary core algorithm engine YiduCore, YIDU TECH has established a closed-loop flywheel of "data-algorithm-scenario," achieving high-efficiency innovation and low-cost scalable application of AI technology, empowering intelligent decision-making across the entire ecosystem of "healthcare-pharmaceutical-insurance-patients."

The core of AI healthcare lies in improving the quality and generation efficiency of medical evidence, optimizing research and development, diagnosis, and treatment processes, ultimately delivering safer, higher-quality, and more accessible medical services. YIDU TECH continuously enhances healthcare service efficiency and accessibility, providing doctors with more precise and efficient decision-making tools, helping pharmaceutical companies shorten the distance from molecules to patients, enabling patients to access more affordable precision diagnosis and treatment, and providing public systems with more scientific support.

The value of medical AI is reflected in the respect for every individual life and the protection of health and well-being.

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10